Cargando…

Estimating the Risks and Benefits of Tamoxifen for Prophylactic Breast Cancer Chemoprevention in Korea

PURPOSE: According to the National Surgical Adjuvant Breast and Bowel Project P1 (NSABP-P1) study, tamoxifen can prevent 49% of invasive breast cancers in patients who have a 5-year risk of 1.67% or more. Because tamoxifen is associated with both adverse effects (endometrial cancer, stroke, pulmonar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Dong Uk, Min, Jun Won, Kim, You-Me, Chang, Myung-Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3318174/ https://www.ncbi.nlm.nih.gov/pubmed/22493628 http://dx.doi.org/10.4048/jbc.2012.15.1.51

Ejemplares similares

Breast cancer chemoprevention: beyond tamoxifen
por: Fabian, Carol J
Publicado: (2001)

Chemoprevention: beyond tamoxifen
por: Cuzick, J
Publicado: (2005)

Economic evaluation of chemoprevention of breast cancer with tamoxifen and raloxifene among high-risk women in Japan
por: Kondo, M, et al.
Publicado: (2009)

Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen
por: Bychkovsky, Brittany, et al.
Publicado: (2022)

Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations
por: Duffy, S W, et al.
Publicado: (2002)

Perceptions of Prophylactic Mastectomy in Korea
por: Yoon, Han Young, et al.
Publicado: (2016)

Estimates of benefits and harms of prophylactic use of aspirin in the general population
por: Cuzick, J., et al.
Publicado: (2015)

Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells
por: Phuong, Nguyen Thi Thuy, et al.
Publicado: (2015)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
por: Moon, Seo Yun, et al.
Publicado: (2021)

Feature of amenorrhea in postoperative tamoxifen users with breast cancer
por: Kim, Hoon, et al.
Publicado: (2017)

Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
por: Wegman, Pia, et al.
Publicado: (2005)

Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis
por: Eggemann, Holm, et al.
Publicado: (2020)

Chemoprevention for Breast Cancer
por: Pruthi, Sandhya, et al.
Publicado: (2015)

Chemoprevention of N‐Nitroso‐N‐methylurea‐induced Rat Mammary Cancer by Miso and Tamoxifen, Alone and in Combination
por: Gotoh, Takahiko, et al.
Publicado: (1998)

Tamoxifen Resistance in Breast Cancer
por: Chang, Minsun
Publicado: (2012)

Performance of Screening Mammography: A Report of the Alliance for Breast Cancer Screening in Korea
por: Lee, Eun Hye, et al.
Publicado: (2016)

The effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer
por: Lee, Seul, et al.
Publicado: (2018)

Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment
por: Campbell, Aideen M, et al.
Publicado: (2018)

Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer
por: Jerevall, Piiha-Lotta, et al.
Publicado: (2010)

Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer
por: Woo, Hye In, et al.
Publicado: (2017)

Estimated Amount of 24-Hour Urine Sodium Excretion Is Positively Correlated with Stomach and Breast Cancer Prevalence in Korea
por: Park, Jung Hwan, et al.
Publicado: (2014)

The antioxidant and chemopreventive potentialities of Mosidae (Adenophora remotiflora) leaves
por: Kim, Ae-Jung, et al.
Publicado: (2010)

Chemopreventive role of green tea in head and neck cancers
por: Kim, Yoo Suk, et al.
Publicado: (2014)

High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer
por: Paulsson, Janna, et al.
Publicado: (2016)

Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group.
por: Decensi, A., et al.
Publicado: (1998)

CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment
por: Beelen, K., et al.
Publicado: (2013)

Estimation of the burden of major cancers in Korea.
por: Yoon, Seok-Jun, et al.
Publicado: (2002)

Effect of Different Types of Mammography Equipment on Screening Outcomes: A Report by the Alliance for Breast Cancer Screening in Korea
por: Choi, Bo Hwa, et al.
Publicado: (2019)

Phyto-oestrogens and breast cancer chemoprevention
por: Limer, Jane L, et al.
Publicado: (2004)

Chemoprevention for breast cancer: current status
por: Boyle, P
Publicado: (2004)

Decision aids for breast cancer chemoprevention
por: Juraskova, Ilona, et al.
Publicado: (2013)

Natural Products for Chemoprevention of Breast Cancer
por: Ko, Eun-Yi, et al.
Publicado: (2015)

Chemoprevention of Breast Cancer by Dietary Polyphenols
por: Mocanu, Maria-Magdalena, et al.
Publicado: (2015)

Endogenous estrogens—breast cancer and chemoprevention
por: Starek-Świechowicz, Beata, et al.
Publicado: (2021)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Knockdown of vps54 aggravates tamoxifen-induced cytotoxicity in fission yeast
por: Lee, Sol, et al.
Publicado: (2021)

Effects of Combined Pentadecanoic Acid and Tamoxifen Treatment on Tamoxifen Resistance in MCF−7/SC Breast Cancer Cells
por: To, Ngoc Bao, et al.
Publicado: (2022)

Chemopreventive and Anticancer Activities of Allium victorialis var. platyphyllum Extracts
por: Kim, Hyun-Jeong, et al.
Publicado: (2014)

Invasive fungal infection in liver transplant recipients in a prophylactic era: A multicenter retrospective cohort study in Korea
por: Kim, Youn Jeong, et al.
Publicado: (2019)

Oestrogen receptor co-activator AIB1 is a marker of tamoxifen benefit in postmenopausal breast cancer
por: Weiner, M., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_okueae6g0ui5mfn13kfo1883sf